Protagonist Therapeutics (PTGX) Equity Ratio (2017 - 2025)
Historic Equity Ratio for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 0.92.
- Protagonist Therapeutics' Equity Ratio rose 442.43% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 442.43%. This contributed to the annual value of 0.91 for FY2024, which is 359.32% down from last year.
- Latest data reveals that Protagonist Therapeutics reported Equity Ratio of 0.92 as of Q3 2025, which was up 442.43% from 0.93 recorded in Q2 2025.
- Protagonist Therapeutics' Equity Ratio's 5-year high stood at 0.94 during Q4 2023, with a 5-year trough of 0.86 in Q4 2021.
- Moreover, its 5-year median value for Equity Ratio was 0.88 (2021), whereas its average is 0.89.
- In the last 5 years, Protagonist Therapeutics' Equity Ratio skyrocketed by 8729.3% in 2021 and then plummeted by 402.05% in 2024.
- Protagonist Therapeutics' Equity Ratio (Quarter) stood at 0.86 in 2021, then increased by 0.78% to 0.87 in 2022, then grew by 8.16% to 0.94 in 2023, then decreased by 3.59% to 0.91 in 2024, then grew by 1.44% to 0.92 in 2025.
- Its Equity Ratio stands at 0.92 for Q3 2025, versus 0.93 for Q2 2025 and 0.93 for Q1 2025.